Trends on SGX Nifty indicate a positive opening for the broader index in India, with an 11 points gain, or 0.09 percent
A break below 10,637 levels will indicate a resumption of the downtrend in the market.
The company had posted a profit of Rs 91.84 crore in the same quarter last fiscal, Pfizer said in a regulatory filing.
The merger of Pfizer’s Upjohn division and Mylan may not only attempt to solve their problems in the US market but also make inroads into emerging markets, particularly China
A revolving door is a practice where people in highly influential positions in the government move to jobs in the private sector and vice-versa.
The company has also been pushing its '15 in 5' plan to launch 15 experimental treatments, each with at least $1 billion annual sales potential, over a five-year period and has been investing in cancer drugs and gene therapies.
Revenue from operations for the March quarter stood at Rs 535.66 crore. It was at Rs 519.95 crore for the year-ago period.
Pfizer's total income was Rs 578.14 crore during the quarter under review. It was Rs 488.62 crore in the corresponding quarter a year ago.
A gap-up opening is likely as Nifty Futures on Singaporean Exchange were trading over 70 points higher. The futures traded around 10,908-odd levels.
Both plants came under Pfizer's ownership after it acquired Hospira in the US.
GSK said it would have a 68-percent controlling equity interest in the GSK Consumer Healthcare joint venture that will have combined sales of about 9.8 billion pounds ($12.7 billion, 10.9 billion euros).
The revamp is the boldest move yet by GSK Chief Executive Emma Walmsley, who took over last year.
The company had posted a net profit of Rs 111.15 crore for the corresponding period of the previous fiscal.
The only saving grace is 10,200 rising trendline support zone on the weekly chart which the Nifty has just managed to hold above.
Centrum recommended hold rating on Pfizer with a target price of Rs 3100 in its research report dated September 10, 2018.
International Paper APPM, Mahindra Logistics and Pfizer reported strong set of earnings for the quarter ended June 2018.
Standalone revenue from operations of the company stood at Rs 512.31 crore for the April-June quarter of the current fiscal. It was Rs 432.59 crore for the year-ago period.
The rollback came a day after Trump took aim at Pfizer and other U.S. drugmakers for raising prices on some of their medicines, saying in a tweet that they "should be ashamed" and that his administration would respond.
At this juncture, markets are clearly experiencing their corrective phases (price wise as well as time-wise) and hence, one should not venture into it aggressively.
Trends on SGX Nifty indicate a positive opening for the broader index in India, a rise of 25 points or 0.24 percent. Nifty futures were trading around 10,656-level on the Singaporean Exchange.